Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Florbetapir (18F) Centiloid Calibration Study
NCT02120664Phase 1Completed
- Sponsor
- Avid Radiopharmaceuticals
- Start
- Apr 2014
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of florbetapir (18F) in Alzheimer's disease (AD) (2 arms), sponsored by Avid Radiopharmaceuticals. Primary endpoint: Florbetapir SUVr Conversion to Centiloid Units. Started Apr 2014; status: completed.
02
Drugs
florbetapir (18F)
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02120664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02120664.